Selected 2003 M&A Transactions

Selected 2003 M&A Transactions

Publication

In 2003, we handled more than 100 M&A transactions. In the past five years, we have completed more than 700 mergers and acquisitions valued in excess of $100 billion. The following are selected highlights from our 2003 transactions:

  • Alnylam Pharmaceuticals — merger with Ribopharma — undisclosed
  • Applix — sale of CRM business to Platinum Equity — $8.75 million
  • Bookham Technology — pending acquisition of New Focus — $330.5 million
  • Braintree Laboratories — sale of worldwide rights to PhosLo® (calcium acetate) to Nabi Biopharmaceuticals — $101 million
  • Casella Waste Systems — acquisition of Hardwick Sanitary Landfill — undisclosed
  • CCBN — acquisition of corporate earnings call transcript and webcast distribution business from Fair Disclosure Financial Network — undisclosed
  • CMGI — sale of AltaVista to Overture Services — $140 million
  • Diacrin — merger with GenVec — $40.4 million
  • DoubleClick — acquisition of CSC Advanced Database Solutions — undisclosed
  • Fabric Networks — merger with Lane15 Software — undisclosed
  • Idenix Pharmaceuticals — acquisition of 51% interest by Novartis — $255 million
  • IDX Systems — sale of EDiX to Total eMed — $64 million
  • LTX Corporation — acquisition of StepTech — undisclosed
  • Manufacturers' Services Limited — pending acquisition by Celestica — $293 million
  • MapInfo — acquisition of Thompson Associates — $13 million plus earnout
  • Penwest Pharmaceuticals — sale of excipient business to Josef Rettenmaier Holding — $41.75 million
  • Proton Energy Systems — pending acquisition of Northern Power Systems — $27.5 million plus warrants
  • SpeechWorks International — acquisition by ScanSoft — $132 million
  • uDate.com — acquisition by USA Interactive — $150 million
  • VitalWorks — acquisition of Amicas — $30 million plus earnout
  • Winphoria Networks — acquisition by Motorola — $175 million

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.